HC Wainwright Lowers Niagen Bioscience (NASDAQ:NAGE) Price Target to $11.00

Niagen Bioscience (NASDAQ:NAGE) had its price target cut by investment analysts at HC Wainwright from $12.00 to $11.00 in a research note issued to investors on Monday,Benzinga reports. The firm currently has a “buy” rating on the stock. HC Wainwright’s price target points to a potential upside of 163.79% from the company’s previous close.

Other analysts also recently issued reports about the stock. Canaccord Genuity Group dropped their target price on shares of Niagen Bioscience from $13.00 to $10.00 and set a “buy” rating on the stock in a report on Tuesday, May 5th. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Niagen Bioscience in a research note on Tuesday, April 21st. Finally, Wall Street Zen cut shares of Niagen Bioscience from a “buy” rating to a “hold” rating in a research note on Saturday, April 25th. Three investment analysts have rated the stock with a Buy rating and one has issued a Hold rating to the company’s stock. According to data from MarketBeat.com, Niagen Bioscience presently has an average rating of “Moderate Buy” and a consensus price target of $14.67.

Niagen Bioscience Stock Performance

Shares of NAGE stock opened at $4.17 on Monday. The company has a market capitalization of $332.12 million, a P/E ratio of 19.86 and a beta of 2.17. The company’s 50 day moving average price is $4.74 and its two-hundred day moving average price is $5.82. Niagen Bioscience has a 52 week low of $4.04 and a 52 week high of $14.69.

Niagen Bioscience (NASDAQ:NAGE) last announced its earnings results on Wednesday, May 6th. The company reported $0.07 EPS for the quarter, topping the consensus estimate of $0.06 by $0.01. The firm had revenue of $31.47 million for the quarter. Niagen Bioscience had a net margin of 14.29% and a return on equity of 22.68%. Analysts forecast that Niagen Bioscience will post 0.23 earnings per share for the current year.

Hedge Funds Weigh In On Niagen Bioscience

Hedge funds and other institutional investors have recently made changes to their positions in the company. Hillsdale Investment Management Inc. bought a new position in shares of Niagen Bioscience in the third quarter valued at $2,988,000. JPMorgan Chase & Co. bought a new position in shares of Niagen Bioscience in the third quarter valued at $3,678,000. Gamco Investors INC. ET AL bought a new position in shares of Niagen Bioscience in the third quarter valued at $1,170,000. Navellier & Associates Inc. bought a new position in shares of Niagen Bioscience in the third quarter valued at $1,768,000. Finally, Gabelli Funds LLC bought a new position in shares of Niagen Bioscience in the third quarter valued at $1,749,000. 15.41% of the stock is owned by institutional investors.

Niagen Bioscience Company Profile

Niagen Bioscience, Inc is a global bioscience company, which engages in acquiring, developing, and commercializing proprietary-based ingredient technologies. It is pioneering research on nicotinamide adenine dinucleotide (NAD+). The company’s patent portfolio includes Nicotinamide Riboside (NR) and other NAD+ precursors, which are commercialized as the flagship ingredient Niagen. It operates through the following segments: Consumer Products, Ingredients, and Analytical Reference Standards and Services.